A method of reducing epileptiform activity in the brain of a subject and/or treating in said subject one or more conditions selected from the group consisting of Alzheimer's disease, epilepsy, Parkinson's disease, heart failure, traumatic brain injury, stroke, hemorrhagic shock, acute lung injury after fluid resuscitation, acute kidney injury, myocardial infarction, myocardial ischemia, diabetes, glioblastoma multiforme, diabetic neuropathy, prostate cancer, amyotrophic lateral sclerosis, Huntington's disease, cutaneous T cell lymphoma, multiple myeloma, peripheral T cell lymphoma, HIV, and Niemann-Pick Type C disease said method comprising:
- administering to said subject, a therapeutically effective amount of a compound of the Formula:
- or a compound of Formula II:
- or salts, solvates or hydrates thereof, wherein:
- R4 is H or C(1-6) alkyl or substituted alkyl;
- and
- R5 and R6 are independently unsubstituted or substituted C(4-30) alky.